4th World Congress on

Scope & Importance

Infectious Diseases and Antimicrobial Resistance Market Overview:

The infectious diseases and antimicrobial resistance (AMR) market is growing as drug-resistant infections rise worldwide. The antibiotic resistance segment is valued at USD 9.3 billion in 2025 and projected to reach USD 12.1 billion by 2030 (CAGR 5.5%). Growth is fueled by increasing cases, public–private funding, and regulatory support. Asia-Pacific leads the market, South America shows the fastest growth, and pneumonia remains the largest disease segment.

The AMR diagnostics market, worth USD 4.6 billion in 2024, is expected to hit USD 6.7 billion by 2030 (CAGR 6.6%). Demand is rising for rapid, point-of-care tests, especially PCR-based technologies. North America currently dominates, but India and other emerging economies are expanding quickly, driven by the need for early detection and better antibiotic stewardship.

The AMR surveillance market is valued at USD 6.24 billion in 2025 and forecasted to reach USD 8.23 billion by 2030 (CAGR 5.7%). Growth is driven by molecular diagnostics, AI-powered analytics, and government programs. North America holds the largest share, while Asia-Pacific is the fastest-growing region. Hospitals remain the main users, with diagnostic labs gaining momentum.

Target Audience:

Physicians | Internists | Clinicians | Infectious Disease Specialists | Microbiologists | Virologists | Bacteriologists | Parasitologist | Medical Students, Researchers, Residents Epidemiologists | Immunologists | Pharmacologists |Antimicrobial Stewardship Experts | Infection Control Officers | Healthcare Practitioners, Nurses | Allied Health Professionals, Physician Assistants | Pharmaceutical Researcher | Drug Discovery Scientists, Clinical Laboratory Scientists | Laboratory Technicians, Hospitals, Medical Colleges | Research Institutes, Pharmaceutical Industries | Biotechnology Companies, Drug Manufacturing Companies | Healthcare Workers and Druggist | Industries

Infectious Diseases and Antimicrobial Resistance Market Overview in USA:

The U.S. infectious diseases market is one of the most advanced globally, valued at over USD 24 billion in 2025, with a projected CAGR of 6–7% through 2030. Growth is driven by increasing hospital-acquired infections (affecting nearly 1 in 31 patients daily, CDC) and viral threats such as influenza, RSV, and COVID-19 variants. The U.S. for a significant share of global revenues, with the influenza vaccine market alone expected to exceed USD 6.5 billion by 2028. Advanced diagnostic platforms, particularly rapid molecular tests, also expanding at a CAGR of nearly 9%, reflecting the demand for early detection and containment of outbreaks. Antimicrobial resistance remains a major challenge, causing 2.8 million infections and 35,000 deaths annually in the U.S. (CDC, 2023).

Valued at USD 3.5–4 billion in 2025, and expected to grow at a CAGR of 5% due to rising resistance in pathogens such as E. coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa. Federal funding has increased, with initiatives like CARB-X awarding over USD 360 million to early-stage AMR projects and BARDA investing more than USD 1 billion in advanced-stage antibiotic and diagnostic development. Rapid diagnostic tests for AMR are also gaining traction, with adoption projected to grow 2x by 2030.

Looking ahead, the U.S. infectious diseases and AMR market is poised for steady expansion, projected to reach USD 33–35 billion by 2030. Government incentives such as the FDA’s QIDP designation, which provides market exclusivity and priority review for new antibiotics, are encouraging innovation. However, the market faces hurdles: the average cost of antibiotic R&D exceeds USD 1.5 billion, while uptake remains slow due to stewardship programs and reimbursement challenges. Despite these barriers, strong federal support and industry investment position the U.S. as a global leader in infectious disease management, with increasing focus on next-generation antibiotics, vaccines, and precision diagnostics to combat AMR.

Infectious Diseases and Antimicrobial Resistance Market Overview in Europe:

The commercial landscape in Europe is being reshaped by hard epidemiology and rising stewardship pressure. AMR is linked to 35,000+ deaths every year in the EU/EEA and an estimated 865,000+ resistant infections annually; the economic drag is ~€11.7 billion per year (PPP) across EU/EEA economies, a recurrent burden that continues to justify spend on novel antibiotics, rapid diagnostics, and infection-prevention solutions. On the demand side, antibiotic consumption fell sharply by 17% from 2018 to 2021, then rebounded to 19.8 DDD/1,000/day in 2023 (vs. 20.1 in 2018)—signalling renewed utilization post-pandemic and exposing variation across member states that vendors must factor into go-to-market plans. In 2023, about 90% of use sat in the community (18.3 DDD/1,000/day) versus 1.6 in hospitals, keeping primary care channels central for stewardship tech and point-of-care diagnostics.

Policy and funding are strong tailwinds. The 2023 EU Council Recommendation sets One-Health targets on IPC, stewardship and national action plan execution, while the Commission and ECDC ramp guidance and monitoring—creating compliance-driven demand for surveillance and IPC solutions. The EU’s health security arm HERA commands ~€2.8 billion (EU4Health) and ~€1.7 billion (Horizon Europe) for 2022–2027, and recent calls include a €13 million instrument for rapid point-of-care susceptibility testing—clear signals for diagnostics innovators. For 2025 specifically, the EU4Health work programme allocates €357.6 million to HERA actions, with procurement and grants as key vehicles—relevant for scale-up pathways and public tenders. amplify transmission of resistant pathogens. Together, these drivers underscore both the urgency of policy and market interventions and the strong opportunity for solutions spanning novel antibiotics, rapid diagnostics, infection-control systems, and stewardship programs. high population density and poor sanitation.

Market access is also moving: Europe has approved new agents (e.g., Emblaveo and Exblifep) for difficult Gram-negative infections, expanding the treatable addressable market while emphasizing antimicrobial stewardship frameworks at launch. Meanwhile, lawmakers debate transferable exclusivity vouchers (TEVs) as a pull incentive—industry sees them as catalytic, while public-health groups raise affordability and spillover concerns. Whichever design prevails, a predictable EU pull-incentive is the swing factor for late-stage pipeline investment and partnering decisions through 2030.

Infectious Diseases and Antimicrobial Resistance in Asia:

The infectious diseases and antimicrobial resistance (AMR) market in Asia is expanding rapidly, driven by rising infection rates, high antibiotic misuse, and increasing healthcare investments. The Asia-Pacific antibiotic resistance market was valued at USD 2.34 billion in 2023 and is projected to reach USD 3.57 billion by 2030, reflecting a CAGR of about 6.2%. In parallel, the AMR diagnostics segment is expected to grow from USD 1.05 billion in 2024 to USD 1.64 billion in 2030, at a 7.8% CAGR, while the antimicrobial susceptibility testing (AST) market is forecast to expand from USD 627.6 million in 2023 to USD 967.5 million by 2030 (CAGR 6.4%). These figures show that Asia is becoming a key growth hub for both therapeutic and diagnostic solutions in AMR, reflecting both the severity of the regional burden and growing demand for stewardship technologies.

The health burden of AMR in Asia is particularly severe. Globally, 5 million deaths in 2019 were linked to AMR, of which 1.27 million were directly attributable. South Asia recorded some of the world’s highest mortality, with 21.5 deaths per 100,000 population due to AMR, while Southeast and East Asia saw 11.7 per 100,000. In the WHO South-East Asia Region alone, sepsis accounted for 4 million deaths in 2019, and up to 1.41 million of these were linked to bacterial AMR. For India, the estimated toll was 297,000 deaths from resistance in a single year. Resistance trends are worsening: between 2016 and 2021, E. coli susceptibility to imipenem fell from 86% to 64%, while Klebsiella pneumoniae dropped from 65% to 43%. In 2021, carbapenem resistance in Acinetobacter baumannii reached 87.5%, and methicillin-resistant Staphylococcus aureus (MRSA) rose from 28.4% to 42.6% over the same period.

Behavioral and systemic factors continue to accelerate resistance across Asia. Self-medication rates for antibiotics range from 9% to 62% across the region, often linked to misconceptions about their effectiveness against viral infections like colds and flu. In Indonesia, around 75% of respondents believed antibiotics could treat viral illnesses, while in China, more than half of people reported antibiotic use within six months, with about 5% sourcing drugs online. Meanwhile, the agricultural sector is a major contributor: antibiotic use in animal husbandry across China and India is projected to double by 2030, creating spillover risks into human populations. The pace of urbanization is another driver, with Asia expected to host 27 of the world’s 43 megacities by 2030.

Universities and Research Institutes:

USA

EUROPE

University of Oxford / University of Cambridge / Imperial College London / University College London / London School of Hygiene & Tropical Medicine / King’s College London / University of Edinburgh / University of Glasgow / University of Manchester / University of Copenhagen / University of Aarhus / University of Helsinki / University of Turku / Karolinska Institute / Uppsala University / Stockholm University / University of Gothenburg / Lund University / University of Oslo / University of Bergen / University of Amsterdam / Leiden University / Utrecht University / Erasmus University Rotterdam / Radboud University Nijmegen / University of Groningen / University of Paris-Saclay / Sorbonne University / Pasteur Institute Paris / University of Strasbourg / University of Geneva / University of Lausanne / University of Zurich / ETH Zurich / University of Basel / University of Vienna / Medical University of Vienna / University of Munich (LMU) / Technical University of Munich (TUM) / University of Heidelberg / Charité – Universitätsmedizin Berlin

Asia/Middle East

University of Tokyo / Kyoto University / Osaka University / Tohoku University / Nagoya University / Keio University / National University of Singapore / Nanyang Technological University / Singapore University of Technology and Design / Chinese University of Hong Kong / University of Hong Kong / Peking University / Tsinghua University / Fudan University / Shanghai Jiao Tong University / Zhejiang University / Sun Yat-sen University / Seoul National University / KAIST – Korea Advanced Institute of Science & Technology / Yonsei University / Korea University / Indian Institute of Science, Bangalore / All India Institute of Medical Sciences, New Delhi / University of Delhi / Banaras Hindu University / King Saud University / King Abdulaziz University / Weill Cornell Medicine – Qatar / Qatar University / American University of Beirut / Tel Aviv University / Hebrew University of Jerusalem / University of Tehran / Sharif University of Technology / University of Jordan / Kuwait University / Sultan Qaboos University / United Arab Emirates University / King Fahd University of Petroleum & Minerals/ University of Baghdad

Hospital and Medical centers

USA

Mayo Clinic / Massachusetts General Hospital / Brigham and Women’s Hospital / UCSF Medical Center / University of Michigan Hospitals and Health Centers / Mount Sinai Hospital, New York / NewYork Presbyterian Hospital / Memorial Sloan Kettering Cancer Center / Stanford Health Care / Duke University Hospital / University of Pennsylvania Health System / Northwestern Memorial Hospital / Vanderbilt University Medical Center / University of Washington Medical Center / University of Chicago Medical Center / Cedars-Sinai Medical Center / Baylor University Medical Center / Rush University Medical Center / University of Pittsburgh Medical Center / Emory University Hospital / Indiana University Health Medical Center / University of California, Los Angeles Medical Center / University of Texas Southwestern Medical Center / Cleveland Clinic Florida / Hospital of the University of Pennsylvania / Oregon Health & Science University Hospital / University of Colorado Hospital / Mount Sinai Beth Israel / NYU Langone Health / Mayo Clinic Phoenix Henry Ford Health System / University of Iowa Hospitals and Clinics / University of Minnesota Medical Center / University of North Carolina Hospitals / Thomas Jefferson University Hospitals / University of Kentucky Albert B. Chandler Hospital

EUROPE

Charité – Universitätsmedizin Berlin / University Hospital Heidelberg / University Hospital Munich (LMU) / University Hospital Hamburg-Eppendorf / University Hospital Frankfurt / University Hospital Cologne / University Hospital Leipzig / Karolinska University Hospital, Stockholm / Sahlgrenska University Hospital, Gothenburg /Uppsala University Hospital / Rigshospitalet, Copenhagen / Odense University Hospital /Aarhus University Hospital / University Hospital Zurich / University Hospital Basel /University Hospital Basel / University Hospital Geneva / Lausanne University Hospital / University Hospital Vienna / Medical University of Vienna Hospital / University Hospital Paris-Saclay / Saint-Louis Hospital, Paris / Assistance Publique – Hôpitaux de Paris (AP-HP) / University Hospital Strasbourg / University Hospital Bordeaux / University Hospital Lyon / University Hospital Grenoble / University Hospital Lille / University Hospital Toulouse / University Hospital Marseille / University Hospital Leuven, Belgium / University Hospital Ghent, Belgium / Erasmus MC, Rotterdam / Amsterdam University Medical Center / Leiden University Medical Center / Utrecht University Medical Center / Radboud University Medical Center / University Hospital Oslo / University Hospital Bergen

Asia/Middle East

The University of Tokyo Hospital / Kyoto University Hospital / Osaka University Hospital / Tohoku University Hospital / Nagoya University Hospital / Keio University Hospital / National University Hospital, Singapore /Singapore General Hospital / Tan Tock Seng Hospital, Singapore / Chinese University of Hong Kong Medical Centre /Queen Mary Hospital, Hong Kong / Peking University First Hospital / Peking Union Medical College Hospital / Fudan University Zhongshan Hospital / Ruijin Hospital, Shanghai / Zhejiang University Sir Run Run Shaw Hospital / Sun Yat-sen University First Affiliated Hospital / Seoul National University Hospital / Asan Medical Center, Seoul / Samsung Medical Center, Seoul / Yonsei University Severance Hospital / India – All India Institute of Medical Sciences (AIIMS), New Delhi / Christian Medical College (CMC), Vellore / King Faisal Specialist Hospital & Research Centre, Riyadh / King Khalid University Hospital, Riyadh / King Abdulaziz University Hospital, Jeddah / Weill Cornell Medicine – Qatar / Hamad Medical Corporation, Qatar / American University of Beirut Medical Center /Hadassah Medical Center, Jerusalem /Sheba Medical Center, Tel Aviv /Tel Aviv Sourasky Medical Center / Shariati Hospital, Tehran / Tehran University Medical Center / King Hussein Cancer Center, Jordan / Royal Medical Services, Jordan / Sultan Qaboos University Hospital, Oman / United Arab Emirates University Hospital / Cleveland Clinic Abu Dhabi

Companies and Industries

USA

Pfizer / Moderna / Johnson & Johnson / Merck & Co. / Gilead Sciences / Amgen / Biogen / Regeneron Pharmaceuticals / Bristol-Myers Squibb / Eli Lilly and Company / Vertex Pharmaceuticals / Novavax / AbbVie / Genentech / Illumina / Thermo Fisher Scientific / Bio-Rad Laboratories / Emergent BioSolutions / Inovio Pharmaceuticals / ModernaTX / Vir Biotechnology / Moderna Therapeutics / Moderna Biotech / Moderna Inc / Moderna Labs / Moderna Research / Moderna Vaccine Division / Moderna Therapeutics Inc / Moderna Biologics / Moderna Immunology / Moderna Clinical / Moderna BioTech / Moderna Pharma / Moderna R&D /Moderna Healthcare / Moderna Development / Moderna Innovations / Moderna Global

EUROPE

GlaxoSmithKline (GSK), UK / AstraZeneca, UK / Bayer AG, Germany / Novartis, Switzerland / Roche, Switzerland /    Sanofi, France / BioNTech, Germany / BioNTech, Germany / Lonza Group, Switzerland / Merck KGaA, Germany / Boehringer Ingelheim, Germany / UCB Pharma, Belgium / Ipsen, France / CSL Behring, Switzerland / Evotec, Germany / Valneva, France / Oxford Biomedica, UK / Abcam, UK / Qiagen, Netherlands / Vectura Group, UK / Galapagos NV, Belgium / Genmab, Denmark / Moderna Europe / CureVac, Germany / Bavarian Nordic, Germany / Seqirus, UK / Morphosys, Germany / BioMerieux, France / Sartorius, Germany / Nabriva Therapeutics, Austria / Orion Corporation, Finland / MedImmune, UK / Adaptimmune, UK / Horizon Discovery, UK / Exscientia, UK /Oxford Nanopore Technologies, UK / Syncona, UK /Cytiva, Sweden / Evaxion Biotech, Denmark / Moderna Switzerland

Asia/Middle East

Samsung Biologics, South Korea / Celltrion, South Korea /LG Chem Life Sciences, South Korea / Takeda Pharmaceutical, Japan / Daiichi Sankyo, Japan / Astellas Pharma, Japan / Fujifilm Diosynth Biotechnologies, Japan / Shionogi & Co., Japan / Eisai Co., Japan / Bharat Biotech, India / Serum Institute of India, India / Zydus Cadila, India / Dr. Reddy’s Laboratories, India / Lupin Limited, India / Biocon, India / WuXi AppTec, China / Sinovac Biotech, China / CanSino Biologics, China / Beijing Institute of Biotechnology, China / Shanghai RAAS Blood Products, China / Shanghai Fosun Pharma, China / China National Biotec Group (CNBG), China / Moderna China / CureVac Asia / BioNTech Asia / Boehringer Ingelheim Asia / G42 Healthcare, UAE / Julphar Pharmaceuticals, UAE / Hikma Pharmaceuticals, Jordan / King Faisal Specialist Hospital & Research Centre Biotech, Saudi Arabia / Saudi Vaccine & Biotech Center / Qatar Biomedical Research Institute / Weill Cornell Medicine – Qatar Biotech / Teva Pharmaceuticals Middle East / Biologix, Israel / Pluristem Therapeutics, Israel / Evogene, Israel / Redhill Biopharma, Israel / Moderna Middle East

Societies and Associations

USA

American Society for Microbiology (ASM) / American Society for Virology (ASV) / American Society for Immunology (ASI) / American Association of Immunologists (AAI) / Society for Immunotherapy of Cancer (SITC) / Federation of American Societies for Experimental Biology (FASEB) / American Pathology Association / College of American Pathologists (CAP) / American Society for Clinical Pathology (ASCP) / Infectious Diseases Society of America (IDSA) / Society for Healthcare Epidemiology of America (SHEA) / American College of Allergy, Asthma & Immunology (ACAAI) / American College of Rheumatology (ACR) / American Society of Hematology (ASH) / Society for Leukocyte Biology (SLB) / Association of Pathology Chairs (APC) / Society for Experimental Biology and Medicine (SEBM) / Clinical Immunology Society (CIS) /American Association of Veterinary Laboratory Diagnosticians (AAVLD) / Society for Mucosal Immunology (SMI) / American College of Medical Genetics and Genomics (ACMG) / Association for Molecular Pathology (AMP) / Society for Pediatric Research (SPR) / American Society for Blood and Marrow Transplantation (ASBMT) / American College of Surgeons – Pathology Section / American Society for Investigative Pathology (ASIP) / Society for Immunotherapy of Cancer (SITC) / American College of Clinical Pharmacy – Immunology / American College of Clinical Pharmacy – Immunology / American College of Allergy, Asthma & Immunology (ACAAI) / Society for Virology Research / American College of Toxicology (ACT) / American Society for Bone and Mineral Research (ASBMR) / American College of Neuropsychopharmacology (ACNP) / American Society of Transplantation (AST) / American Heart Association – Immunology Section / American Diabetes Association – Immunology Section / Association for Pathology Informatics (API) / Society for Experimental Biology and Medicine (SEBM) / American College of Physicians – Pathology Section /

EUROPE

Immunology (EAACI) / European Society for Organ Transplantation (ESOT) / European Society of Clinical Immunology (ESCI) / European Society for Blood and Marrow Transplantation (EBMT) / European Society of Paediatric Infectious Diseases (ESPID) / European Society of Human Genetics (ESHG) /European Society for Gene and Cell Therapy (ESGCT) / European Society for Immunotherapy of Cancer (ESIC) /European Federation of Immunological Societies (EFIS) / European Society for Clinical Virology (ESCV) / European Society for Experimental Biology (ESEB) / European Society for Immunopathology (ESIP) /European Society for Laboratory Medicine (ESLM) / European College of Veterinary Pathologists (ECVP) / European Society for Molecular Imaging (ESMI) / European Society for Clinical Virology and Immunology (ESCVI) / European Society of Transplantation Immunology Section (EST-IS) / European Society for Paediatric Allergy and Immunology (ESPAI)

Asia/Middle East

Asian Society for Virology (ASV) / Asia Pacific Society for Immunology (APSI) / Japanese Society for Immunology (JSI) / Indian Immunology Society (IIS) / Indian Association of Pathologists and Microbiologists (IAPM) / Korean Society for Immunology (KSI) / Chinese Society for Immunology (CSI) / Chinese Society for Microbiology (CSM) / Taiwan Society for Microbiology and Immunology (TSMI) / Thai Society for Immunology (TSI) / Singapore Immunology Network (SIgN) / Hong Kong Society for Microbiology (HKSM) / Saudi Society for Microbiology and Infectious Diseases (SSMID) / Saudi Society for Pathology (SSP) /Israeli Society for Microbiology (ISM) / Qatar Biomedical Research Society (QBRS) / Emirates Society for Immunology (ESI) / UAE Society for Pathology and Laboratory Medicine (UAE SPLM) / Turkish Society of Microbiology and Immunology (TSMI) /

Societies and Associations

USA

• American Society for Microbiology (ASM) / American Society for Virology (ASV) / American Society for Immunology (ASI) / American Association of Immunologists (AAI) / Society for Immunotherapy of Cancer (SITC) / Federation of American Societies for Experimental Biology (FASEB) / American Pathology Association / College of American Pathologists (CAP) / American Society for Clinical Pathology (ASCP) / Infectious Diseases Society of America (IDSA) / Society for Healthcare Epidemiology of America (SHEA) / American College of Allergy, Asthma & Immunology (ACAAI) / American College of Rheumatology (ACR) / American Society of Hematology (ASH) / Society for Leukocyte Biology (SLB) / Association of Pathology Chairs (APC) / Society for Experimental Biology and Medicine (SEBM) / Clinical Immunology Society (CIS) /American Association of Veterinary Laboratory Diagnosticians (AAVLD) / Society for Mucosal Immunology (SMI) / American College of Medical Genetics and Genomics (ACMG) / Association for Molecular Pathology (AMP) /Society for Pediatric Research (SPR) / American Society for Blood and Marrow Transplantation (ASBMT) / American College of Surgeons – Pathology Section / American Society for Investigative Pathology (ASIP) /Society for Immunotherapy of Cancer (SITC) / American College of Clinical Pharmacy – Immunology / American College of Clinical Pharmacy – Immunology / American College of Allergy, Asthma & Immunology (ACAAI) / Society for Virology Research / American College of Toxicology (ACT) / American Society for Bone and Mineral Research (ASBMR) / American College of Neuropsychopharmacology (ACNP) / American Society of Transplantation (AST) / American Heart Association – Immunology Section / American Diabetes Association – Immunology Section / Association for Pathology Informatics (API) / Society for Experimental Biology and Medicine (SEBM) / American College of Physicians – Pathology Section /

EUROPE

• Immunology (EAACI) / European Society for Organ Transplantation (ESOT) / European Society of Clinical Immunology (ESCI) / European Society for Blood and Marrow Transplantation (EBMT) / European Society of Paediatric Infectious Diseases (ESPID) / European Society of Human Genetics (ESHG) / European Society for Gene and Cell Therapy (ESGCT) / European Society for Immunotherapy of Cancer (ESIC) /European Federation of Immunological Societies (EFIS) / European Society for Clinical Virology (ESCV) / European Society for Experimental Biology (ESEB) / European Society for Immunopathology (ESIP) /European Society for Laboratory Medicine (ESLM) / European College of Veterinary Pathologists (ECVP) / European Society for Molecular Imaging (ESMI) / European Society for Clinical Virology and Immunology (ESCVI) / European Society of Transplantation Immunology Section (EST-IS) / European Society for Paediatric Allergy and Immunology (ESPAI)

Asia/Middle East

• Asian Society for Virology (ASV) / Asia Pacific Society for Immunology (APSI) / Japanese Society for Immunology (JSI) / Indian Immunology Society (IIS) / Indian Association of Pathologists and Microbiologists (IAPM) / Korean Society for Immunology (KSI) / Chinese Society for Immunology (CSI) / Chinese Society for Microbiology (CSM) / Taiwan Society for Microbiology and Immunology (TSMI) / Thai Society for Immunology (TSI) / Singapore Immunology Network (SIgN) / Hong Kong Society for Microbiology (HKSM) / Saudi Society for Microbiology and Infectious Diseases (SSMID) / Saudi Society for Pathology (SSP) /Israeli Society for Microbiology (ISM) / Qatar Biomedical Research Society (QBRS) / Emirates Society for Immunology (ESI) / UAE Society for Pathology and Laboratory Medicine (UAE SPLM) / Turkish Society of Microbiology and Immunology (TSMI) /